GILEAD SCIENCES, INC.

Q1 2025 13F Holdings Report, Stock Holdings

Signature - Title
Andrew D. Dickinson - Executive Vice President and Chief Financial Officer
Location
Foster City, CA
Holdings as of
31 Mar 2025
Value $
$1,181,331,731
Num holdings
14
Filing time
13 May 2025, 16:15:37 UTC
Form type
13F-HR
Description
All US holdings of this investor are reported in this report. Top holdings included ACLX, GLPG, RCUS, ASMB, and MRUS.
Previous filing
Q4 2024 - 13 Feb 2025
Next filing
Q2 2025 - 14 Aug 2025
Sym Weight Trade Impact Company Class Share Change Activity Value Change $ Value $ * Price $ Shares Principal
Filing 2025 Q1 compared to 2024 Q4 by default. Changes are calculated vs the previous SEC filing.
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.

Person Signing this Report on Behalf of Reporting Manager:

Name Title City, State Date
Andrew D. Dickinson Executive Vice President and Chief Financial Officer Foster City, California 13 May 2025

Other Included Managers (1):

Num Name Location File Number
1 Gilead Therapeutics A1 Unlimited Co Co Cork, Ireland 028-25083